To enhance service speed and avoid tariff delays, we've opened a US warehouse. All US orders ship directly from our US facility.
| Cat. No. | Product Name | Field of Application | Chemical Structure |
|---|---|---|---|
| DCC1868 | Dshs00884 |
Non-toxic human papillomavirus E6 inhibitor
More description
|
|
| DCC1867 | Dsba Inhibitor F1 |
Pathogen motility inhibitor of EcDsbA
More description
|
|
| DCC1866 | Ds79932728 |
Novel Potent, Orally Available G9a/GLP Inhibitor for Treating β-Thalassemia and Sickle Cell Disease
More description
|
|
| DCC1865 | Ds42450411 |
Novel potent orally active hepcidin production inhibitor
More description
|
|
| DCC1864 | Ds-3801b Hydrochloride |
Novel non-macrolide GPR38 agonist
More description
|
|
| DCC1863 | Ds37571084 |
Novel and orally bioavailable PTHR1 antagonist
More description
|
|
| DCC1862 | Ds28120313 |
Novel potent orally active hepcidin production inhibitor
More description
|
|
| DCC1861 | Ds19161384 |
Novel selective PPARγ modulator, resulting in robust plasma glucose reductions with excellent DMPK profiles
More description
|
|
| DCC1860 | Ds08210767 |
Novel potent PTHR1 antagonist
More description
|
|
| DCC1859 | Drostanolone Propionate |
Inhibitor of the growth of estrogen receptor-presenting breast cancers
More description
|
|
| DCC1858 | Dropropizine |
Oral non-opioid anti-tussive agent for treatment of cough
More description
|
|
| DCC1857 | Dri-c91005 |
Novel inhibitor of the interaction of hACE2 with the spike proteins of SARS-CoV-2 as well as SARS-CoV
More description
|
|
| DCC1856 | Dri-c23041 |
Novel inhibitor of the interaction of hACE2 with the spike proteins of SARS-CoV-2 as well as SARS-CoV
More description
|
|
| DCC1855 | Dp-v-4 |
Novel Dual PROTAC for Simultaneous Degradation of EGFR and PARP
More description
|
|
| DCC1854 | D-propargylglycine |
Click chemistry tool molecule in probing peptidoglycan (PG)
More description
|
|
| DCC1853 | Dpre1-in-377790 |
Novel DprE1 inhibitor, killing M. tuberculosis
More description
|
|
| DCC1852 | Dppe Hydrochloride |
Substrate of CYP3A and inhibitor of P-glycoprotein
More description
|
|
| DCC1851 | Dpp8/9-in-8j |
Novel selective DPP8/9 inhibitor, blocking AML progression in vivo
More description
|
|
| DCC1850 | Dpp7-in-5385 |
Novel inhibitor of dipeptidyl peptidase 7 (DPP7)
More description
|
|
| DCC1849 | Dpi-287 |
Novel highly selective agonist for the δ-opioid receptor, producing less convulsions than most drugs from this family and having antidepressant-like effects
More description
|
|
| DCC1848 | Dpf-p10 |
First Potent Small Molecule Ligand for MALAT1
More description
|
|
| DCC1847 | Dp-c-1 |
Novel Dual PROTAC for Simultaneous Degradation of EGFR and PARP
More description
|
|
| DCC1846 | Dpbx-l-dopa |
Novel boron-containing dopa-derivative, acting as a bladder relaxant through non-catecholamine receptors
More description
|
|
| DCC1845 | Dpb163-ae |
Novel 2-aminoethyl diphenylborinate (2-APB) analogue, inducing a profound activation of SOCE in DT40 cells, albeit at low concentrations (10 nM), blocking the melatonin-induced [Ca ] cyt increase and SOCE in P. falciparum.
More description
|
|
| DCC1844 | Dpa-154 |
Novel effective and selective inhibitor of E. coli topoisomerase I
More description
|
|
| DCC1843 | Dp-326 |
Novel antibacterial with activity against the Gram-negative bacteria associated with nosocomial infections
More description
|
|
| DCC1842 | Dov51892 |
Agonist of GABAA receptors α15 subunits
More description
|
|
| DCC1841 | Dothiepin Hydrochloride |
Tricyclic antidepressant (TCA), acting as a serotonin–norepinephrine reuptake inhibitor (SNRI) and also having other activities including antihistamine, antiadrenergic, antiserotonergic, anticholinergic, and sodium channel-blocking effects
More description
|
|
| DCC1840 | Doramectin |
Anthelmintic, for the treatment of parasites such as gastrointestinal roundworms, lungworms, eyeworms, grubs, sucking lice and mange mites in cattle
More description
|
|
| DCC1839 | Dora 42 |
Dual orexin receptor antagonist (OX1R and OX2R antagonist or DORA)
More description
|
|